BioSphere Medical, Inc.

Type: Public
On the web: http://www.biospheremed.com
Employees: 80

BioSphere Medical's products are very well rounded. The firm is developing its bioengineered acrylic bead microspheres for use in embolotherapy, a process in which materials are injected into the bloodstream to cut blood flow to tumors. The company's EmboSphere and EmboGold Microspheres treat hypervascularized tumors (tumors with a large number of blood vessels feeding them) but not specifically for uterine fibroids, a key therapy target. BioSphere is also developing microspheres to treat liver tumors and deliver cancer-fighting drugs to tumors, as well as to repair, regenerate, and bulk tissue. Sepracor owns nearly 25% of the company.

Key numbers for fiscal year ending December, 2007:
Sales: $26.9M
One year growth: 17.5%
Net income: ($1.9)M

Officers:
Chairman: David P. Southwell
President, CEO, and Director: Richard J. (Rick) Faleschini
EVP and CFO: Martin J. (Marty) Joyce

Competitors:
Boston Scientific
Cook Group
Johnson & Johnson